Figure 3.

Estimation of mean blood management cost savings (€ +) or incremental cost (€−) per patient in patients undergoing surgery for total knee arthroplasty, managed with a blood conservation device (A. Bellovac ABT, Wellspect HealthCare; B. ConstaVac CBC II, Stryker), or with no reinfusion (control), for different pre-operative haemoglobin levels and cost scenarios.

Data calculation takes into account the costs per patient for both autologous and allogeneic blood management (cost scenario ALO-1), plus a hospital stay prolonged for 1 day (cost scenario ALO-2) or 2 days (cost scenario ALO-3) in patients receiving allogeneic red cell transfusion (see Table IV).

*p<0.05, reinfusion group vs control group.